RecruitingEarly Phase 1

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

China30 participantsStarted 2023-07-05

Plain-language summary

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 and above.
✓. Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
✓. Liver and kidney function is within acceptable ranges.
✓. Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.
✓. Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.
✓. Patients need to be capable of participating in follow-up visits and treatment plans.

Exclusion criteria

✕. History of allergy to JAK inhibitors.
✕. Pregnant or breastfeeding women.
✕. Severe infectious conditions.
✕. History of central nervous system demyelinating diseases.
✕. History of lymphoproliferative diseases.
✕. Active and latent tuberculosis.
✕. HIV carriers with a CD4+ T cell count lower than (\<200/mL).
✕. Active HBV/HCV infection.

What they're measuring

Time to Reepithelization

Timeframe: up to 8 week

Trial details

NCT IDNCT06119490

SponsorPeng Zhang

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07

Contact for this trial

Chao Ji

+86 18651619908 jichaofy@fjmu.edu.cn

View on ClinicalTrials.gov More Toxic Epidermal Necrolysis trials